AR and posterior cortical atrophy: Phase 2 trials of different neoadjuvant therapies for localized high-risk PCa have tested multiple combinations of hormonal and chemohormonal therapies, including second- and third-generation androgen receptor–targeting (AR-targeting) agents (8–13), cytotoxic chemotherapy (14–16), and immunotherapy (17–19).